Chad Cowan - Crispr Therapeutics Scientific Founder
| CRSP Stock | USD 46.29 0.97 2.05% |
Insider
Chad Cowan is Scientific Founder of Crispr Therapeutics AG
| Address | Baarerstrasse 14, Zug, Switzerland, 6300 |
| Phone | 41 41 561 32 77 |
| Web | https://www.crisprtx.com |
Chad Cowan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Chad Cowan against Crispr Therapeutics stock is an integral part of due diligence when investing in Crispr Therapeutics. Chad Cowan insider activity provides valuable insight into whether Crispr Therapeutics is net buyers or sellers over its current business cycle. Note, Crispr Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Crispr Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Chad Cowan over a month ago Insider Trading |
Crispr Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0957) % which means that it has lost $0.0957 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1307) %, meaning that it created substantial loss on money invested by shareholders. Crispr Therapeutics' management efficiency ratios could be used to measure how well Crispr Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/22/2024, Return On Tangible Assets is likely to drop to -0.07. In addition to that, Return On Capital Employed is likely to grow to -0.1. As of 11/22/2024, Total Current Liabilities is likely to drop to about 63.5 M. In addition to that, Liabilities And Stockholders Equity is likely to drop to about 1.3 BSimilar Executives
| Showing other executives | INSIDER Age | ||
| Rachel Haurwitz | Intellia Therapeutics | 38 | |
| Edward III | Fate Therapeutics | 48 | |
| Mark Shearman | Editas Medicine | 64 | |
| FACC MD | Verve Therapeutics | 61 | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Nicole Gaudelli | Beam Therapeutics | N/A | |
| MS MBA | Fate Therapeutics | N/A | |
| Harry III | Editas Medicine | 63 | |
| Jason MBA | Caribou Biosciences | 56 | |
| Cindy Hayashi | Caribou Biosciences | N/A | |
| Andrew MD | Verve Therapeutics | 45 | |
| Andreas Orth | Krystal Biotech | 54 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Marcus Schindler | Novo Nordisk AS | 58 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Gloria Lin | Krystal Biotech | N/A | |
| Bruce Eaton | Editas Medicine | 70 | |
| William Ciambrone | Sarepta Therapeutics | 60 | |
| Ruhi MBA | Caribou Biosciences | 49 | |
| Mary Jenkins | Sarepta Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0957 |
Crispr Therapeutics Leadership Team
Elected by the shareholders, the Crispr Therapeutics' board of directors comprises two types of representatives: Crispr Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Crispr. The board's role is to monitor Crispr Therapeutics' management team and ensure that shareholders' interests are well served. Crispr Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Crispr Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samarth Kulkarni, Chief Business Officer | ||
| James JD, General Secretary | ||
| Susan Kim, Vice Relations | ||
| Craig Mello, Scientific Member | ||
| Lawrence Klein, Chief Officer | ||
| Chad Cowan, Scientific Founder | ||
| Rodger MD, Chairman Founder | ||
| Daniel Anderson, Scientific Member | ||
| Emmanuelle Charpentier, CoFounder Member | ||
| Raju Prasad, Chief Officer | ||
| Matthew MD, Scientific Member | ||
| Stephen Kennedy, Head Operations | ||
| James Kasinger, General Counsel, Secretary to the Board of Directors | ||
| Julianne MBA, Chief Officer | ||
| Brendan MBA, CFO VP | ||
| MD FACP, Chief Officer | ||
| Shaun Foy, Founder |
Crispr Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Crispr Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0957 | ||||
| Profit Margin | (1.18) % | ||||
| Operating Margin | (182.94) % | ||||
| Current Valuation | 2.33 B | ||||
| Shares Outstanding | 85.35 M | ||||
| Shares Owned By Insiders | 1.71 % | ||||
| Shares Owned By Institutions | 72.21 % | ||||
| Number Of Shares Shorted | 18.59 M | ||||
| Price To Earning | 17.33 X |
Pair Trading with Crispr Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Crispr Stock
| 0.35 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.35 | KTTA | Pasithea Therapeutics | PairCorr |
| 0.35 | PALI | Palisade Bio | PairCorr |
| 0.33 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.